Actinogen Medical launches $5m digital-only share purchase plan for retail investors

Actinogen Medical ( (AU:ACW) ) has provided an update.

Actinogen Medical has launched a share purchase plan offering eligible shareholders in Australia, New Zealand and, in limited cases, the United States the chance to subscribe for up to $30,000 of new shares at $0.042 each without brokerage. The company aims to raise up to $5 million before costs, with potential oversubscriptions subject to ASX rules, and is distributing all offer documents and applications electronically via its share registry portal, with the offer closing on 24 February 2026.

The move underscores Actinogen’s continued reliance on retail shareholder support to strengthen its balance sheet and fund its operations, while also aligning with a broader market shift toward digital-only capital raisings to reduce printing and mailing costs. Existing investors who participate can increase their exposure at a set price within a defined window, while the electronic-only process may streamline administration but requires shareholders to engage online or request mailed copies and still complete payments via electronic channels.

The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.

More about Actinogen Medical

Actinogen Medical Limited is an Australian-listed biopharmaceutical company focused on developing therapies in the medical sector, with its shareholder base primarily located in Australia and New Zealand and some investors in the United States. The company’s ordinary shares trade on the ASX, and it is using equity capital markets to fund its ongoing activities and growth plans.

YTD Price Performance: -29.51%

Average Trading Volume: 6,164,363

Technical Sentiment Signal: Hold

Current Market Cap: A$137.3M

See more insights into ACW stock on TipRanks’ Stock Analysis page.